Business, energy, technology, markets and global industry news from Business News Today

HNSCC

PharmaDeviceNews HNSCC
Representative image: Oncology researchers reviewing head and neck cancer imaging data, reflecting the clinical focus of Inhibrx Biosciences’ INBRX-106 HexAgon study update in first-line HNSCC and the broader immuno-oncology race to improve pembrolizumab-based treatment strategies.
Pharma & Biotech

Inhibrx’s HexAgon study may test whether smarter OX40 design can beat old failures

OX40 biology has promised more than it proved. Inhibrx now needs INBRX-106 to show pembrolizumab can work harder in HNSCC.

Read More
Pharma & Biotech

Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?

Byondis is showcasing two new ADC technology platforms at AACR 2026. Read why antifolate and phosphonate payloads could reshape oncology innovation.

Read More
Pharma & Biotech

Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?

CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.

Read More